Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Common Equity (2016 - 2025)

Altimmune (ALT) has disclosed Common Equity for 16 consecutive years, with $224.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 82.09% to $224.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $224.9 million through Dec 2025, up 82.09% year-over-year, with the annual reading at $224.9 million for FY2025, 82.09% up from the prior year.
  • Common Equity for Q4 2025 was $224.9 million at Altimmune, up from $185.6 million in the prior quarter.
  • The five-year high for Common Equity was $246.4 million in Q1 2021, with the low at $123.5 million in Q4 2024.
  • Average Common Equity over 5 years is $182.1 million, with a median of $185.1 million recorded in 2022.
  • The sharpest move saw Common Equity surged 488.2% in 2021, then plummeted 36.37% in 2024.
  • Over 5 years, Common Equity stood at $199.1 million in 2021, then dropped by 6.95% to $185.3 million in 2022, then rose by 4.75% to $194.1 million in 2023, then tumbled by 36.37% to $123.5 million in 2024, then skyrocketed by 82.09% to $224.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $224.9 million, $185.6 million, and $161.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.